A retrospective study of 177Lu-PSMA-617 therapy in metastatic prostate cancer patients
Latest Information Update: 04 Jun 2021
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2021 New trial record